IFP Advisors Inc Buys 54,983 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

IFP Advisors Inc grew its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 44.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 178,547 shares of the biopharmaceutical company’s stock after acquiring an additional 54,983 shares during the quarter. IFP Advisors Inc owned 0.11% of TG Therapeutics worth $5,374,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. boosted its holdings in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares during the last quarter. Synergy Asset Management LLC bought a new position in shares of TG Therapeutics during the 4th quarter worth approximately $75,000. GAMMA Investing LLC boosted its stake in shares of TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 2,171 shares during the last quarter. KBC Group NV boosted its stake in shares of TG Therapeutics by 30.5% in the 3rd quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,092 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of TG Therapeutics in the third quarter valued at approximately $111,000. Institutional investors own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TGTX. TD Cowen started coverage on TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. StockNews.com lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. Finally, The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $40.67.

Insiders Place Their Bets

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 10.50% of the company’s stock.

TG Therapeutics Trading Down 6.0 %

Shares of TGTX opened at $29.02 on Tuesday. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $36.84. The business has a 50-day moving average of $30.96 and a 200 day moving average of $27.90. The firm has a market cap of $4.52 billion, a P/E ratio of -290.17 and a beta of 2.26. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.